Patients with hepatic impairment generally do not require dose adjustment, as semaglutide is not extensively metabolized by the liver
The decision to prescribe these medications should weigh the substantial metabolic benefits against individual gallbladder risk, recognizing that for most patients, the cardiovascular and glycemic advantages outweigh the relatively modest absolute risk increase
Early evidence suggests that GLP-1s can also help people with breast cancer and obesity lose weight, which may improve their prognosis
Will it keep me awake
If all appeals fail and you still need the medication, your options are paying cash for branded GLP-1s (Wegovy retail is around $1,350 per month, Zepbound around $1,060), using the manufacturer savings programs from Novo Nordisk or Eli Lilly, or pursuing compounded semaglutide or tirzepatide through a licensed telehealth provider
These two compounds work through entirely different mechanisms